Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red; macrogol 3000; indigo carmine aluminium lake - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; indigo carmine aluminium lake; hypromellose; iron oxide yellow; triacetin; iron oxide red; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red; macrogol 3000; indigo carmine aluminium lake - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Estats Units - anglès - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - prucalopride succinate (unii: 4v2g75e1ck) (prucalopride - unii:0a09iuw5tp) - motegrity® is indicated for the treatment of chronic idiopathic constipation (cic) in adults. motegrity is contraindicated in patients with: - a history of hypersensitivity to motegrity. reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed [(see adverse reactions (6.2)] . - intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as crohn's disease, ulcerative colitis, and toxic megacolon/megarectum. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to motegrity during pregnancy. healthcare providers are encouraged to register patients by contacting mothertobaby pregnancy studies conducted by the organization of teratology information specialists (otis) at 1-877-311-8972 or visiting https://mothertobaby.org/pregnancy-studies/. risk summary available data from case reports with prucaloprid

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - prucalopride succinate; prucalopride -

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - prucalopride succinate - oral tablet - 1mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - prucalopride succinate - oral tablet - 2mg